25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

NXTG (Nextage Therapeutics Ltd) Stock Analysis
Buy, Hold or Sell?

Let's analyze Nextage Therapeutics Ltd together

I guess you are interested in Nextage Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Nextage Therapeutics Ltd’s Financial Insights
  • 📈 Technical Analysis (TA) – Nextage Therapeutics Ltd’s Price Targets

I'm going to help you getting a better view of Nextage Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Nextage Therapeutics Ltd

I send you an email if I find something interesting about Nextage Therapeutics Ltd.

1. Quick Overview

1.1. Quick analysis of Nextage Therapeutics Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Nextage Therapeutics Ltd? (30 sec.)

How much money do you get?

How much money do you get?
ILA0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
ILA-16.43
Expected worth in 1 year
ILA-49.65
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
ILA-33.23
Return On Investment
-33.2%

For what price can you sell your share?

Current Price per Share
ILA100.00
Expected price per share
ILA56.00 - ILA113.80
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Nextage Therapeutics Ltd (5 min.)




Live pricePrice per Share (EOD)
ILA100.00
Intrinsic Value Per Share
ILA-22.54 - ILA35.51
Total Value Per Share
ILA-38.96 - ILA19.08

2.2. Growth of Nextage Therapeutics Ltd (5 min.)




Is Nextage Therapeutics Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?-$1.6m-$815.9k-$834.3k-50.6%

How much money is Nextage Therapeutics Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$978.6k-$1.1m$177.6k18.2%
Net Profit Margin-794.9%-442.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Nextage Therapeutics Ltd (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Nextage Therapeutics Ltd?

Welcome investor! Nextage Therapeutics Ltd's management wants to use your money to grow the business. In return you get a share of Nextage Therapeutics Ltd.

First you should know what it really means to hold a share of Nextage Therapeutics Ltd. And how you can make/lose money.

Speculation

The Price per Share of Nextage Therapeutics Ltd is ILA100.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nextage Therapeutics Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nextage Therapeutics Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ILA-16.43. Based on the TTM, the Book Value Change Per Share is ILA-8.31 per quarter. Based on the YOY, the Book Value Change Per Share is ILA-6.86 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ILA0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nextage Therapeutics Ltd.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 ILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per Share
Usd Eps-0.030.0%-0.030.0%-0.030.0%-0.040.0%-0.06-0.1%-0.06-0.1%
Usd Book Value Change Per Share-0.020.0%-0.020.0%-0.020.0%-0.020.0%-0.020.0%-0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.020.0%-0.020.0%-0.020.0%-0.020.0%-0.020.0%-0.010.0%
Usd Price Per Share0.23-0.23-0.10-0.17-0.42-0.32-
Price to Earnings Ratio-8.06--8.06--2.91--4.83--6.12--4.88-
Price-to-Total Gains Ratio-9.45--9.45--4.88--11.72--32.40--19.59-
Price to Book Ratio-4.78--4.78--4.12--18.31-32.21-20.20-
Price-to-Total Gains Ratio-9.45--9.45--4.88--11.72--32.40--19.59-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.2981
Number of shares3354
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.02-0.02
Usd Total Gains Per Share-0.02-0.02
Gains per Quarter (3354 shares)-83.05-54.55
Gains per Year (3354 shares)-332.20-218.19
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-332-3420-218-228
20-664-6740-436-446
30-997-10060-655-664
40-1329-13380-873-882
50-1661-16700-1091-1100
60-1993-20020-1309-1318
70-2325-23340-1527-1536
80-2658-26660-1746-1754
90-2990-29980-1964-1972
100-3322-33300-2182-2190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.08.00.00.0%0.08.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%2.06.00.025.0%2.06.00.025.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.08.00.0%0.00.08.00.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%2.06.00.025.0%2.06.00.025.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Nextage Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---8.306-8.3060%-6.858-17%-5.987-28%-5.456-34%-2.054-75%
Book Value Per Share---16.429-16.4290%-8.122-51%-8.605-48%-3.996-76%-0.107-99%
Current Ratio--0.0540.0540%0.238-77%0.365-85%0.876-94%1.144-95%
Debt To Asset Ratio--16.68316.6830%3.500+377%7.155+133%4.597+263%3.165+427%
Debt To Equity Ratio----0%-0%-0%0.361-100%0.529-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--2056331063.5002056331063.5000%745656200.000+176%1523121434.500+35%4355560284.700-53%3121405152.938-34%
Eps---9.743-9.7430%-11.511+18%-12.614+29%-21.631+122%-20.578+111%
Ev To Sales Ratio--49.79049.7900%8.512+485%29.151+71%341.481-85%208.089-76%
Free Cash Flow Per Share---2.359-2.3590%-6.713+185%-8.975+280%-11.080+370%-12.728+439%
Free Cash Flow To Equity Per Share---2.359-2.3590%-6.713+185%-8.975+280%-7.600+222%-5.731+143%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--35.508----------
Intrinsic Value_10Y_min---22.536----------
Intrinsic Value_1Y_max---6.287----------
Intrinsic Value_1Y_min---8.946----------
Intrinsic Value_3Y_max---11.387----------
Intrinsic Value_3Y_min---21.247----------
Intrinsic Value_5Y_max---7.441----------
Intrinsic Value_5Y_min---27.279----------
Market Cap3369720000.000+21%2645231063.5002645231063.5000%1128856200.000+134%1911754767.833+38%4716260284.700-44%3564742652.938-26%
Net Profit Margin---7.949-7.9490%-4.428-44%-4.126-48%-36.178+355%-28.110+254%
Operating Margin----0%-0%-0%-22.3480%-21.1540%
Operating Ratio--10.14310.1430%6.295+61%5.479+85%23.556-57%20.858-51%
Pb Ratio-6.087-27%-4.778-4.7780%-4.124-14%-18.313+283%32.212-115%20.198-124%
Pe Ratio-10.264-27%-8.057-8.0570%-2.910-64%-4.825-40%-6.125-24%-4.884-39%
Price Per Share100.000+22%78.50078.5000%33.500+134%56.733+38%139.960-44%105.788-26%
Price To Free Cash Flow Ratio-42.386-27%-33.273-33.2730%-4.991-85%-13.841-58%-17.380-48%-12.035-64%
Price To Total Gains Ratio-12.039-27%-9.451-9.4510%-4.885-48%-11.718+24%-32.401+243%-19.588+107%
Quick Ratio--0.0080.0080%0.068-88%0.028-72%0.140-94%0.185-96%
Return On Assets---9.300-9.3000%-3.542-62%-5.513-41%-4.454-52%-3.085-67%
Return On Equity----0%-0%-0%-2.2020%-1.6080%
Total Gains Per Share---8.306-8.3060%-6.858-17%-5.987-28%-5.456-34%-2.054-75%
Usd Book Value---1650281.600-1650281.6000%-815899.700-51%-864390.633-48%-401421.460-76%-10768.863-99%
Usd Book Value Change Per Share---0.025-0.0250%-0.020-17%-0.018-28%-0.016-34%-0.006-75%
Usd Book Value Per Share---0.049-0.0490%-0.024-51%-0.026-48%-0.012-76%0.000-99%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--6129922.9006129922.9000%2222801.132+176%4540424.996+35%12983925.209-53%9304908.761-34%
Usd Eps---0.029-0.0290%-0.034+18%-0.038+29%-0.064+122%-0.061+111%
Usd Free Cash Flow---236989.500-236989.5000%-674302.200+185%-901553.767+280%-1112986.160+370%-1278550.900+439%
Usd Free Cash Flow Per Share---0.007-0.0070%-0.020+185%-0.027+280%-0.033+370%-0.038+439%
Usd Free Cash Flow To Equity Per Share---0.007-0.0070%-0.020+185%-0.027+280%-0.023+222%-0.017+143%
Usd Market Cap10045135.320+21%7885433.8007885433.8000%3365120.332+134%5698940.963+38%14059171.909-44%10626497.848-26%
Usd Price Per Share0.298+22%0.2340.2340%0.100+134%0.169+38%0.417-44%0.315-26%
Usd Profit---978662.300-978662.3000%-1156329.900+18%-1267123.733+29%-2172910.520+122%-1974949.763+102%
Usd Revenue--123115.300123115.3000%261135.600-53%128083.633-4%93663.020+31%98969.200+24%
Usd Total Gains Per Share---0.025-0.0250%-0.020-17%-0.018-28%-0.016-34%-0.006-75%
 EOD+6 -2MRQTTM+0 -0YOY+17 -163Y+17 -165Y+17 -1710Y+17 -17

3.3 Fundamental Score

Let's check the fundamental score of Nextage Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-10.264
Price to Book Ratio (EOD)Between0-1-6.087
Net Profit Margin (MRQ)Greater than0-7.949
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.008
Current Ratio (MRQ)Greater than10.054
Debt to Asset Ratio (MRQ)Less than116.683
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-9.300
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Nextage Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose100.000
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Nextage Therapeutics Ltd

Nextage Therapeutics Ltd, a pharmaceutical company, develops cannabinoid-based products. The company was formerly known as Nextage Cannabis Innovation Ltd. and changed its name to Nextage Therapeutics Ltd in August 2020. The company was incorporated in 1982 and is based in Ness Ziona, Israel.

Fundamental data was last updated by Penke on 2025-07-01 22:01:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Nextage Therapeutics Ltd earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Nextage Therapeutics Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -794.9% means that -7.95 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nextage Therapeutics Ltd:

  • The MRQ is -794.9%. The company is making a huge loss. -2
  • The TTM is -794.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-794.9%TTM-794.9%0.0%
TTM-794.9%YOY-442.8%-352.1%
TTM-794.9%5Y-3,617.8%+2,822.9%
5Y-3,617.8%10Y-2,811.0%-806.8%
4.3.1.2. Return on Assets

Shows how efficient Nextage Therapeutics Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nextage Therapeutics Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • -930.0% Return on Assets means that Nextage Therapeutics Ltd generated -9.30 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nextage Therapeutics Ltd:

  • The MRQ is -930.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -930.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-930.0%TTM-930.0%0.0%
TTM-930.0%YOY-354.2%-575.8%
TTM-930.0%5Y-445.4%-484.6%
5Y-445.4%10Y-308.5%-137.0%
4.3.1.3. Return on Equity

Shows how efficient Nextage Therapeutics Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nextage Therapeutics Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.0% Return on Equity means Nextage Therapeutics Ltd generated 0.00 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nextage Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-220.2%+220.2%
5Y-220.2%10Y-160.8%-59.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Nextage Therapeutics Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Nextage Therapeutics Ltd is operating .

  • Measures how much profit Nextage Therapeutics Ltd makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nextage Therapeutics Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated 0.00  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nextage Therapeutics Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-2,234.8%+2,234.8%
5Y-2,234.8%10Y-2,115.4%-119.4%
4.3.2.2. Operating Ratio

Measures how efficient Nextage Therapeutics Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 10.14 means that the operating costs are 10.14 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Nextage Therapeutics Ltd:

  • The MRQ is 10.143. The company is inefficient in keeping operating costs low. -1
  • The TTM is 10.143. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ10.143TTM10.1430.000
TTM10.143YOY6.295+3.848
TTM10.1435Y23.556-13.413
5Y23.55610Y20.858+2.698
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Nextage Therapeutics Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Nextage Therapeutics Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.05 means the company has 0.05 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Nextage Therapeutics Ltd:

  • The MRQ is 0.054. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.054. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.054TTM0.0540.000
TTM0.054YOY0.238-0.184
TTM0.0545Y0.876-0.822
5Y0.87610Y1.144-0.268
4.4.3.2. Quick Ratio

Measures if Nextage Therapeutics Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nextage Therapeutics Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.01 means the company can pay off 0.01 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nextage Therapeutics Ltd:

  • The MRQ is 0.008. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.008. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.008TTM0.0080.000
TTM0.008YOY0.068-0.060
TTM0.0085Y0.140-0.132
5Y0.14010Y0.185-0.045
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Nextage Therapeutics Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Nextage Therapeutics Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nextage Therapeutics Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 16.68 means that Nextage Therapeutics Ltd assets are financed with 1,668.3% credit (debt) and the remaining percentage (100% - 1,668.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Nextage Therapeutics Ltd:

  • The MRQ is 16.683. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 16.683. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ16.683TTM16.6830.000
TTM16.683YOY3.500+13.183
TTM16.6835Y4.597+12.085
5Y4.59710Y3.165+1.432
4.5.4.2. Debt to Equity Ratio

Measures if Nextage Therapeutics Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nextage Therapeutics Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 0.0% means that company has 0.00 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nextage Therapeutics Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.361-0.361
5Y0.36110Y0.529-0.167
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Nextage Therapeutics Ltd generates.

  • Above 15 is considered overpriced but always compare Nextage Therapeutics Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -8.06 means the investor is paying -8.06 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nextage Therapeutics Ltd:

  • The EOD is -10.264. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.057. Based on the earnings, the company is expensive. -2
  • The TTM is -8.057. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.264MRQ-8.057-2.207
MRQ-8.057TTM-8.0570.000
TTM-8.057YOY-2.910-5.147
TTM-8.0575Y-6.125-1.933
5Y-6.12510Y-4.884-1.241
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Nextage Therapeutics Ltd:

  • The EOD is -42.386. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -33.273. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -33.273. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-42.386MRQ-33.273-9.113
MRQ-33.273TTM-33.2730.000
TTM-33.273YOY-4.991-28.283
TTM-33.2735Y-17.380-15.894
5Y-17.38010Y-12.035-5.345
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Nextage Therapeutics Ltd is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Nextage Therapeutics Ltd:

  • The EOD is -6.087. Based on the equity, the company is expensive. -2
  • The MRQ is -4.778. Based on the equity, the company is expensive. -2
  • The TTM is -4.778. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.087MRQ-4.778-1.309
MRQ-4.778TTM-4.7780.000
TTM-4.778YOY-4.124-0.654
TTM-4.7785Y32.212-36.990
5Y32.21210Y20.198+12.013
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in ILS. All numbers in thousands.

Summary
Total Assets353
Total Liabilities5,889
Total Stockholder Equity-5,517
 As reported
Total Liabilities 5,889
Total Stockholder Equity+ -5,517
Total Assets = 353

Assets

Total Assets353
Total Current Assets317
Long-term Assets36
Total Current Assets
Net Receivables 46
Total Current Assets  (as reported)317
Total Current Assets  (calculated)46
+/- 271
Long-term Assets
Property Plant Equipment 36
Long-term Assets  (as reported)36
Long-term Assets  (calculated)36
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,853
Long-term Liabilities36
Total Stockholder Equity-5,517
Total Current Liabilities
Short Long Term Debt 163
Accounts payable 243
Total Current Liabilities  (as reported)5,853
Total Current Liabilities  (calculated)406
+/- 5,447
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt47
Long-term Liabilities  (as reported)36
Long-term Liabilities  (calculated)47
+/- 11
Total Stockholder Equity
Total Stockholder Equity (as reported)-5,517
Total Stockholder Equity (calculated)0
+/- 5,517
Other
Common Stock Shares Outstanding 33,697
Net Debt 163
Net Invested Capital -5,354
Net Working Capital -5,536
Property Plant and Equipment Gross 189



6.2. Balance Sheets Structured

Currency in ILS. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
> Total Assets 
0
12,394
5,476
6,006
4,070
4,272
1,512
1,095
353
3531,0951,5124,2724,0706,0065,47612,3940
   > Total Current Assets 
1,455
3,261
780
1,484
2,512
4,156
1,423
886
317
3178861,4234,1562,5121,4847803,2611,455
       Cash And Cash Equivalents 
0
2,851
481
1,080
2,034
3,263
1,051
404
0
04041,0513,2632,0341,0804812,8510
       Short-term Investments 
0
122
122
122
35
99
0
0
0
00099351221221220
       Net Receivables 
236
180
150
183
435
684
13
253
46
4625313684435183150180236
       Other Current Assets 
0
0
0
0
0
26
0
0
0
0002600000
   > Long-term Assets 
0
9,133
4,696
4,522
1,558
116
89
209
36
36209891161,5584,5224,6969,1330
       Property Plant Equipment 
266
116
88
65
240
116
89
209
36
36209891162406588116266
       Goodwill 
0
3,610
3,610
3,610
0
0
0
0
0
000003,6103,6103,6100
       Intangible Assets 
0
5,393
984
847
1,318
0
0
0
0
00001,3188479845,3930
> Total Liabilities 
0
7,957
7,125
2,350
2,620
3,756
1,938
3,832
5,889
5,8893,8321,9383,7562,6202,3507,1257,9570
   > Total Current Liabilities 
1,772
1,418
1,893
721
1,504
2,575
1,772
3,726
5,853
5,8533,7261,7722,5751,5047211,8931,4181,772
       Short Long Term Debt 
0
0
0
0
194
202
211
232
163
1632322112021940000
       Accounts payable 
224
177
221
48
208
446
136
124
243
24312413644620848221177224
       Other Current Liabilities 
831
561
730
402
35
35
0
0
0
0003535402730561831
   > Long-term Liabilities 
0
6,539
5,232
1,629
1,116
1,181
166
106
36
361061661,1811,1161,6295,2326,5390
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
97
30
0
146
47
47146030970000
       Long-term Liabilities Other 
0
4,871
4,153
1,629
538
66
43
36
36
363643665381,6294,1534,8710
> Total Stockholder Equity
0
4,451
-1,625
3,702
1,450
-253
-895
-2,900
-5,517
-5,517-2,900-895-2531,4503,702-1,6254,4510
   Common Stock
1,096
2,268
2,728
126,002
23,510
29,535
0
0
0
00029,53523,510126,0022,7282,2681,096
   Retained Earnings Total Equity000000000
   Accumulated Other Comprehensive Income 000000000
   Capital Surplus 000000000
   Treasury Stock000000000
   Other Stockholders Equity 
6,532
2,207
1,985
0
0
0
0
0
0
0000001,9852,2076,532



6.3. Balance Sheets

Currency in ILS. All numbers in thousands.




6.4. Cash Flows

Currency in ILS. All numbers in thousands.




6.5. Income Statements

Currency in ILS. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in ILS. All numbers in thousands.

Gross Profit (+$)
totalRevenue413
Cost of Revenue-337
Gross Profit7676
 
Operating Income (+$)
Gross Profit76
Operating Expense-3,852
Operating Income-3,439-3,776
 
Operating Expense (+$)
Research Development130
Selling General Administrative1,469
Selling And Marketing Expenses-
Operating Expense3,8521,599
 
Net Interest Income (+$)
Interest Income0
Interest Expense-27
Other Finance Cost-13
Net Interest Income-40
 
Pretax Income (+$)
Operating Income-3,439
Net Interest Income-40
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-3,470-3,439
EBIT - interestExpense = -27
-3,283
-3,256
Interest Expense27
Earnings Before Interest and Taxes (EBIT)--3,443
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-3,470
Tax Provision--
Net Income From Continuing Ops-3,470-3,470
Net Income-3,283
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-40
 

Technical Analysis of Nextage Therapeutics Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nextage Therapeutics Ltd. The general trend of Nextage Therapeutics Ltd is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nextage Therapeutics Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Nextage Therapeutics Ltd Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Nextage Therapeutics Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 107.00 < 112.40 < 113.80.

The bearish price targets are: 65.90 > 59.20 > 56.00.

Know someone who trades $NXTG? Share this with them.👇

Nextage Therapeutics Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Nextage Therapeutics Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Nextage Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Nextage Therapeutics Ltd.

Nextage Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartNextage Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Nextage Therapeutics Ltd. The current adx is .

Nextage Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Nextage Therapeutics Ltd.

Nextage Therapeutics Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Nextage Therapeutics Ltd.

Nextage Therapeutics Ltd Daily Relative Strength Index (RSI) ChartNextage Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Nextage Therapeutics Ltd.

Nextage Therapeutics Ltd Daily Stochastic Oscillator ChartNextage Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Nextage Therapeutics Ltd.

Nextage Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartNextage Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Nextage Therapeutics Ltd.

Nextage Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartNextage Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Nextage Therapeutics Ltd.

Nextage Therapeutics Ltd Daily Williams %R ChartNextage Therapeutics Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Nextage Therapeutics Ltd.

Nextage Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Nextage Therapeutics Ltd.

Nextage Therapeutics Ltd Daily Average True Range (ATR) ChartNextage Therapeutics Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Nextage Therapeutics Ltd.

Nextage Therapeutics Ltd Daily On-Balance Volume (OBV) ChartNextage Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Nextage Therapeutics Ltd.

Nextage Therapeutics Ltd Daily Money Flow Index (MFI) ChartNextage Therapeutics Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Nextage Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-27CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-28MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-06-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-07-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Nextage Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Nextage Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose100.000
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Nextage Therapeutics Ltd with someone you think should read this too:
  • Are you bullish or bearish on Nextage Therapeutics Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nextage Therapeutics Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Nextage Therapeutics Ltd

I send you an email if I find something interesting about Nextage Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Nextage Therapeutics Ltd.

Receive notifications about Nextage Therapeutics Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.